The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and ...

The glucagon-like peptides GLP-1 and GLP-2 are synthesised and then released from enteroendocrine cells in the small and large intestine. GLP-1 promotes efficient nutrient assimilation while GLP-2 ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing ... which is consistent with maximum stimulation of muscle protein synthesis. Patients can also aim to consume protein three ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

The start-up expects to advance its lead asset—a once-weekly oral glucagon-like peptide 1 (GLP-1) receptor agonist—into Phase 2 trials for weight loss and the treatment of obesity later this year.